Open AccessActivity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens
Author(s) -
Mark Biagi,
A Shajee,
Alesia Vialichka,
M Jurkovic,
Xing Tan,
Eric Wenzler
Publication year - 2020
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.02255-19
Subject(s) - serratia marcescens , meropenem , ceftazidime/avibactam , microbiology and biotechnology , imipenem , carbapenem , broth microdilution , ceftazidime , enterobacteriaceae , serratia , antibacterial agent , biology , medicine , antibiotics , bacteria , antibiotic resistance , minimum inhibitory concentration , escherichia coli , pseudomonas aeruginosa , pseudomonas , biochemistry , genetics , gene
The Serratia marcescens enzyme (SME) is a chromosomally encoded carbapenemase with no known optimal treatment. Various β-lactam/β-lactamase inhibitors and comparators were evaluated against 8 SME producers via broth microdilution. Four isolates were subsequently tested via time-kill analyses. All isolates were resistant to imipenem, imipenem-relebactam, and meropenem but susceptible to ceftazidime, ceftazidime-avibactam, and meropenem-vaborbactam. Ceftazidime, imipenem-relebactam, and meropenem-vaborbactam were bactericidal against 3, 0, and 4 isolates, respectively. Meropenem-vaborbactam may be a potential option for severe SME-producing infections.